Scarica l'app Stockscreener
131.46
0.10%
-0.13
Dopo l'orario di chiusura:
131.46
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Abbott Laboratories Borsa (ABT) Ultime notizie
Abbott Laboratories stock chart pattern explainedJuly 2025 Action & Target Return Focused Picks - Newser
Abbott Labs: Tariffs Cost $200M, US Investments Mitigate ImpactNews and Statistics - IndexBox
Abbott Laboratories CEO warns tariffs are here to stay, points to new US investments - Yahoo Finance
Abbott Labs CEO on tariff hits & big US manufacturing investment - Yahoo Finance
What's Driving Abbott's Gross Margin Growth Amid Macro Issues - The Globe and Mail
Stock Analysis | Abbott Laboratories OutlookNavigating a Volatile Market with Strong Fundamentals - AInvest
Precision Trading with Abbott Laboratories (ABT) Risk Zones - news.stocktradersdaily.com
Published on: 2025-08-27 06:09:50 - Newser
Formula makers have been hiding the truth — and endangering the tiniest babies | Opinion - The Tennessean
Does Abbott Laboratories show high probability of rebound2025 Market Outlook & Free Risk Controlled Daily Trade Plans - Newser
Abbott’s Esprit resorbable stent gains CE mark - BioWorld MedTech
What earnings revisions data tells us about Abbott LaboratoriesMarket Risk Report & Verified Technical Trade Signals - Newser
What institutional flow reveals about Abbott LaboratoriesRisk Management & Verified Technical Signals - Newser
Is Abbott Laboratories' (NYSE:ABT) Stock's Recent Performance A Reflection Of Its Financial Health? - Yahoo Finance
Abbott Laboratories price tries to gather positive momentumForecast today26-08-2025 - Economies.com
Real time breakdown of Abbott Laboratories stock performanceMarket Performance Report & Daily Stock Momentum Reports - Newser
Real time scanner hits for Abbott Laboratories explainedJuly 2025 Spike Watch & Weekly Setup with High ROI Potential - Newser
Abbott's Esprit BTK System: A Game-Changer in PAD Treatment Gains CE Mark and Proves Clinical Superiority - AInvest
Abbott’s Esprit BTK System gains CE mark for PAD treatment - Yahoo Finance
Can a trend reversal in Abbott Laboratories lead to recoveryTrade Exit Summary & Low Risk High Win Rate Picks - Newser
Abbott Slips 0.54 as $0.62 Billion Volume Ranks 112th Amid Institutional Buys and Insider Sells - AInvest
3 Unstoppable Dividend Stocks to Buy Right Now - MSN
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Abbott Laboratories : Dissolving Stent Receives CE Mark, Pioneering a New Era in Peripheral Vascular Treatment - MarketScreener
If You Invested $10K In Abbott Laboratories Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
Analyzing Abbott Laboratories with multi timeframe charts2025 Geopolitical Influence & Consistent Growth Equity Picks - Newser
Published on: 2025-08-25 02:51:07 - Newser
Can technical indicators confirm Abbott Laboratories’s reversalWeekly Trade Recap & Low Risk Profit Maximizing Plans - Newser
Real time pattern detection on Abbott Laboratories stockDay Trade & Precise Buy Zone Tips - Newser
Abbott Laboratories (ABT): Assessing Current Valuation After Recent Share Price Momentum - simplywall.st
With 80% institutional ownership, Abbott Laboratories (NYSE:ABT) is a favorite amongst the big guns - Yahoo Finance
Minnesota Tax Court Cuts Abbott Labs Property Value By $7M - Law360
Abbott Laboratories Stock (ABT) Opinions on Recent Earnings and Insider Trading - Quiver Quantitative
The Zacks Analyst Blog Highlights Amazon.com, Salesforce, Abbott Laboratories and Fossil Group - Yahoo Finance
Top Research Reports for Amazon.com, Salesforce & Abbott - MSN
Abbott Sues Chinese Rival Over Glucose Monitor UK Patent - Law360
Abbott Gets $7 Million Shaved From Tax Value of Minnesota Lab - news.bloombergtax.com
Should You Invest in Abbott (ABT) Based on Bullish Wall Street Views? - Yahoo Finance
Abbott gets 2nd formula lawsuit dismissed, spelling trouble for 700 cases - Crain's Chicago Business
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Alcohol assay from Carolina Liquid Chemistries receives CLIA moderate complexity categorization on Abbott ImmTox™ 270 chemistry analyzer - News-Medical
1 Cash-Producing Stock for Long-Term Investors and 2 We Question - FinancialContent
Synlait mum on rumoured US buyer for 'cash burning' Pōkeno plant - ThePost.co.nz
Abbott Shares Slide 1.12% as Trading Volume Dives 43.81% to 182nd Rank Amid Blood Campaign Push - AInvest
Abbott Laboratories scores a win in federal court, as it faces hundreds of suits over formula for preterm babies - Chicago Tribune
Here's Why We Think Abbott Laboratories (NYSE:ABT) Is Well Worth Watching - 富途牛牛
$1 Million Prize: Abbott and Big Ten's Massive Blood Drive Competition Returns After 12,000 Lives Saved - Stock Titan
Abbott Gains in Nutrition With Adult Segment Leading Growth - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Could Easily Take On More Debt - Yahoo Finance
Synlait to sell plant to Abbott Labs as a2 Milk buys asset from rival - The Australian
Abbott Laboratories Sheds 8% On A Rare Guidance Miss - MSN
0.49%
0.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):